XML 40 R29.htm IDEA: XBRL DOCUMENT

Equity (Tables)

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

Schedule of Equity


			Three Months Ended March 31,
			Common Stock						Other Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Loss			Treasury Stock						Non- controlling Interests			Total
($ and shares in millions except per share amounts)			Shares			Par Value												Shares			Cost
Balance at January 1, 2023			3,577			$	1,788		$	44,379		$	61,081		$	(4,768)		1,039			$	(56,489)		$	67		$	46,058
Net income attributable to Merck & Co., Inc.			—			—			—			2,821			—			—			—			—			2,821
Other comprehensive loss, net of taxes			—			—			—			—			(115)			—			—			—			(115)
Cash dividends declared on common stock ($0.73 per share)			—			—			—			(1,863)			—			—			—			—			(1,863)
Treasury stock shares purchased			—			—			—			—			—			1			(149)			—			(149)
Share-based compensation plans and other			—			—			88			—			—			—			61			—			149
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			4			4

Balance at March 31, 2023			3,577			$	1,788		$	44,467		$	62,039		$	(4,883)		1,040			$	(56,577)		$	71		$	46,905
Balance at January 1, 2024			3,577			$	1,788		$	44,509		$	53,895		$	(5,161)		1,045			$	(57,450)		$	54		$	37,635
Net income attributable to Merck & Co., Inc.			—			—			—			4,762			—			—			—			—			4,762
Other comprehensive loss, net of taxes			—			—			—			—			(113)			—			—			—			(113)
Cash dividends declared on common stock ($0.77 per share)			—			—			—			(1,960)			—			—			—			—			(1,960)
Treasury stock shares purchased			—			—			—			—			—			1			(122)			—			(122)
Share-based compensation plans and other			—			—			89			—			—			(2)			127			1			217
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			5			5

Balance at March 31, 2024			3,577			$	1,788		$	44,598		$	56,697		$	(5,274)		1,044			$	(57,445)		$	60		$	40,424